Methotrexate risks.
- Published in:
- Australian Journal of Pharmacy, 2012, v. 93, n. 1101, p. 24
- Publication type:
- Article
Works matching DE "NPS Pharmaceuticals Inc."
Results: 7
1
2
Cinacalcet: AMG 073, Calcimimetics – Amgen/NPS Pharmaceuticals, KRN 1493, NPS 1493.
- Published in:
- Drugs in R&D, 2003, v. 4, n. 6, p. 349
- By:
- Publication type:
- Article
3
ALX 111: ALX1-11, Parathyroid Hormone (1-84) – NPS Allelix, PREOS™, PTH, Recombinant Human Parathyroid Hormone, rhPTH (1-84).
- Published in:
- Drugs in R&D, 2003, v. 4, n. 4, p. 231
- By:
- Publication type:
- Article
4
Cinacalcet.
- Published in:
- Drugs in R&D, 2003, v. 4, n. 1, p. 39, doi. 10.2165/00126839-200304010-00006
- Publication type:
- Article
5
Full-length human recombinant parathyroid hormone for the treatment of osteoporosis.
- Published in:
- Formulary, 2006, v. 41, n. 5, p. 214
- By:
- Publication type:
- Article
6
Shire acquires NPS Pharmaceuticals for $5.2 billion.
- Published in:
- Optometry Times, 2015, v. 7, n. 2, p. 18
- Publication type:
- Article
7
Shire bags NPS, including newly approved biologic for hypoparathyroidism.
- Published in:
- Nature Biotechnology, 2015, v. 33, n. 3, p. 226, doi. 10.1038/nbt0315-226c
- Publication type:
- Article